23rd Sep 2015 15:04
23 September 2015
Motif Bio plc
("Motif" or the "Company")
Issue of Shares for Exercised Warrants
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants. The exercise price of the warrants was 20 pence. The new Ordinary Shares represent 0.13% of the enlarged issued share capital.
Admission to trading on AIM of the 140,321 new Ordinary Shares, which rank parri passu with the existing Ordinary Shares, is expected on 28 September 2015. Following the allotment, the total issued share capital will increase to 108,486,537 Ordinary Shares with each share holding one voting right.
Enquiries
Motif Bio plc Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com
| ||
|
| |
Zeus Capital Limited (NOMINATED ADVISER and BROKER) | +44 (0)20 7533 7727 | |
Phil Walker/ John Treacy Dominic Wilson
|
| |
Northland Capital Partners Limited (BROKER) | +44 (0) 20 7382 1100 | |
Patrick Claridge/ David Hignell John Howes/ Mark Treharne (Broking)
|
| |
Plumtree Capital Limited (FINANCIAL ADVISOR) |
+49 (0) 89 210 2280 +44 (0) 207 148 5998
| |
Stephen Austin
| +44 (0) 207 183 2493 | |
Yellow Jersey PR Limited (FINANCIAL PR) Dominic Barretto Philip Ranger Charles Goodwin
| +44 (0) 7768 537 739 |
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
Related Shares:
MTFB.L